How about the pharmaceutical intermediates Market in 2019? Many enterprises have increased their orders

[pharmaceutical network market analysis] pharmaceutical intermediates refer to intermediate chemicals made in the process of chemical drug synthesis The upstream is the manufacturing industry of basic chemical raw materials, and the downstream is the manufacturing industry of chemical drug raw materials and preparations In recent years, with the continuous development of China's pharmaceutical intermediates industry, the basic chemical raw materials and pharmaceutical intermediates needed for pharmaceutical production can basically achieve self-sufficiency, only a few intermediates need to be imported, and the export situation of domestic intermediates is good The industry believes that in 2019, with the promotion of generic drug consistency evaluation and the implementation of policies such as volume purchase, pharmaceutical intermediates also ushered in broad market space and good development opportunities, and the future prospects are still promising The production of pharmaceutical intermediates in China has been increasing in recent years, but the production of intermediates fluctuates obviously, and the production of main intermediates has increased According to the analysis report on Market Research and investment forecast of China's pharmaceutical intermediates industry in 2018-2023 issued by prospective industry research institute, the output of penicillin industrial salt decreased by 10.1% year-on-year, the supply and export decreased by 9.6% year-on-year; the output of 7aca decreased by 31%; the output of 6apa decreased by 18.9% year-on-year, and the export decreased by 31.5% The development of pharmaceutical intermediates industry is significantly affected by the development of downstream chemical APIs and chemical pharmaceutical preparations In recent years, under the background of the continuous expansion of the market scale of pharmaceutical manufacturing industry, the market scale of China's pharmaceutical manufacturing industry has been expanding year by year According to the database of China Business Industry Research Institute, from January to December 2018, the national chemical raw drug production was 2.823 million tons, down 1.1% year on year Combined with the situation that affects the development of China 's pharmaceutical manufacturing industry, the industry believes that China' s chemical medicine market will still maintain a rapid development speed It is estimated that by 2020, the market size will reach 878 billion yuan, with a compound growth rate of 5.1% In 2020, the sales volume of chemical medicine market will account for 49% of the whole pharmaceutical market, and the market share will decrease In the case that the prospect of downstream pharmaceutical market is promising, it will also promote the strength of upstream pharmaceutical intermediates The author found that since 2019, many pharmaceutical intermediates companies have expressed in the questions of investors that the sales orders of pharmaceutical intermediates of the company have increased compared with 2018, with a substantial increase in performance In addition, pharmaceutical intermediates of pharmaceutical companies have registered with DMF in major international market countries and China, and have been quoted by customers The products are sold overseas In addition, since the second half of this year, many pharmaceutical enterprises have been arranging pharmaceutical intermediate projects For example, in July, Qingdao bafangda Biotechnology Co., Ltd settled in Nehe with a total investment of 10.3 billion yuan * ST Hehua released a new restructuring draft at the end of August After the completion of the reorganization, * ST Hehua will put out physical assets such as urea, into pharmaceutical intermediate assets, and transform from traditional chemical industry to fine chemical industry In September, Haichen Pharmaceutical Co., Ltd plans to sign the investment cooperation agreement with the administrative committee of Anqing high tech Zone, start the construction of the subproject of API and pharmaceutical intermediates, and lay a solid foundation for the company's future productization, diversification and long-term development In November, Borui pharmaceutical created a high barrier platform, formed high-tech value-added pharmaceutical intermediates and APIs sales, pharmaceutical technology transfer, and cooperative development with other pharmaceutical enterprises with brand or sales channel advantages by using their own technology and product advantages, so as to realize diversification of profit model.